VivoSeq
Oncology

Lung Adenocarcinoma

76

Pipeline Programs↗

24

Active Trials↗

42

Companies Involved↗

Lung Adenocarcinoma is a moderately active landscape with 76 programs across 42 companies. The most active players are Grit Biotechnology, Imclone, Bukwang Pharmaceutical. 14 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

15/100

Mech. Concentration

11/100

Completion Rate

75/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Grit Biotechnology

1 program

Phase 1I

Imclone

1 program

Phase 1B

Bukwang Pharmaceutical

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1Bayer logo

Bayer

2 programs

Phase 2Novartis logo

Novartis

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical7

Platinum

Bristol-Myers Squibb

Ipilimumab

Bristol-Myers Squibb

Iruplinalkib

Qilu Pharmaceutical Co., Ltd.

Veliparib

AbbVie

Chemotherapy（pemetrexed+cisplatin）

Third Military Medical University

Phase 18

Dapagliflozin

AstraZeneca

Nivolumab

Bristol-Myers Squibb

Nintedanib

Boehringer Ingelheim

Cetuximab

Imclone

NK Cells

Southwest Hospital, China

Phase 240

Crizotinib

Prism Pharmaceuticals

Osimertinib

AstraZeneca

Icotinib

Betta Pharmaceuticals Co., Ltd.

Metformin

EMD Serono

Docetaxel

Avyxa

Phase 37

Pembrolizumab

Merck & Co.

Gefitinib

AstraZeneca

Bevacizumab

Bio-Thera Solutions

Vinorelbine

Pierre Fabre Medicament

Lorlatinib

Pfizer

Approved14

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Tepotinib

EMD Serono

Ponatinib

Takeda

Atezolizumab

Roche

Carboplatin

Avyxa

Analysis

Modality Breakdown

81%

Small molecule

62 of 77 classified programs — the dominant modality here.

19%ALL OTHERSMonoclonal antibody1013%Protein / enzyme45%Cell therapy11%

Small molecule leads; the ring shows all 77 classified programs, each share of the total. Modality classified for 100% of 83 pipeline programs.

Analysis

Trial Status

88

clinical trials

Unknown status32 · 36%
Completed24 · 27%
Recruiting13 · 15%
Not yet recruiting7 · 8%
Terminated7 · 8%
Active, not recruiting4 · 5%
Other1 · 1%

Clinical Trials

Trial Activity

88 trials

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy
Recruiting·KKonkuk University Medical Center·Phase 2·NCT05469022·40 enrolled
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Recruiting·LLantern Pharma Inc.·Phase 2·NCT05456256·90 enrolled
Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma
Recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT07235280·48 enrolled
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
Recruiting·PPeking University Shenzhen Hospital·N/A·NCT07374614·20 enrolled
Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
Recruiting·HHebei Medical University Fourth Hospital·N/A·NCT06056115·20 enrolled
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT05503667·96 enrolled
Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients with Advanced Lung Adenocarcinoma
Recruiting·GGrit Biotechnology·Phase 1·NCT06491225·12 enrolled
FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma
Recruiting·SSun Yat-Sen University Cancer Center·Phase 3·NCT07058428·258 enrolled
Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Recruiting·SSamsung Medical Center·Phase 2·NCT05528458·59 enrolled
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06528847·62 enrolled
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma
Recruiting·IInstitut Bergonié·Phase 3·NCT04339218·214 enrolled
Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT06516887·44 enrolled
Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma
Recruiting·SSheba Medical Center·N/A·NCT07636252·400 enrolled
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
Active, not recruiting·—·Phase 4·NCT05689671·136 enrolled
The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02493582·400 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)